Table 1

Cost-effectiveness of different regimens in the Chinese setting

Treatment regimenDC (%)HCC (%)QALYsCosts (US$)Incremental QALYsIncremental costs (US$)ICER
(US$/QALY)
Genotype 2
 PEG-RBV (reference)4.473.6212.15579470
 SOF/VEL0.180.3912.625012 1230.469326535653
 SOF-RBV1.861.6612.472112 0010.316425317999
 SOF-DCV0.180.3912.625014 4820.4693501210 680
Genotype 3
 PEG-RBV (reference)9.507.5513.405912 861
 SOF-DCV1.411.2914.135515 2790.729624183314
 SOF/VEL4.583.8213.884115 5410.478226805604
 SOF-RBV1.231.2314.152820 8340.7469797310 675
Genotype 6
 PEG-RBV (reference)7.416.0214.287415 630
 SOF-RBV0.260.5514.908110 6350.6207−4995−8047
 SOF/VEL0.610.8314.881012 4930.5936−3137−5285
 SOF-DCV0.260.5514.908114 5980.6207−1032−1663
  • DC, decompensated cirrhosis; HCC, hepatocellular carcinoma; ICER, incremental cost-effectiveness ratio; PEG-RBV, pegylated interferon plus ribavirin; QALYs, quality-adjusted life years; SOF-DCV, sofosbuvir and daclatasvir; SOF-RBV, sofosbuvir plus ribavirin; SOF/VEL, sofosbuvir/velpatasvir.